39 results
8-K
EX-99.2
PROK
ProKidney Corp - Ordinary Shares
10 Jun 24
ProKidney Announces Positive Interim REGEN-007 Phase 2 Trial Data and Provides Clinical and Operational Updates
8:00am
clinical Led FDA strategy and engagement for 10+ SaMD products, including practice guidelines Breakthrough, PMA, De Novo, and 510(k) Strong track record
8-K
EX-99.1
PROK
ProKidney Corp - Ordinary Shares
11 Sep 23
Regulation FD Disclosure
8:01am
Registrational Program Regulatory & reimbursement engagement plan: Diabetic Kidney Disease FDA / EMA* HTA Conducting ‘Gold Standard’ Two Adequate and Well
DEF 14A
xipryvytl3m8bp3wphh
26 May 23
Definitive proxy
8:00am
424B3
q73ftsbi ypl8eckvty
21 Apr 23
Prospectus supplement
4:18pm
POS AM
ka0gnm0j1e r8
17 Apr 23
Prospectus update (post-effective amendment)
5:01pm
8-K
EX-99.1
627qxz
8 Sep 22
Regulation FD Disclosure
6:55am
8-K
EX-10.1
6t1ch 5qu8jmw5mfccos
15 Jul 22
Revolutionary Chronic Kidney Disease Therapeutics Company ProKidney to List on the Nasdaq
5:24pm
8-K
EX-10.13
o3oqrl ghjh7
15 Jul 22
Revolutionary Chronic Kidney Disease Therapeutics Company ProKidney to List on the Nasdaq
5:24pm
8-K
gt2c5skvd 0zi4ro66u6
15 Jul 22
Revolutionary Chronic Kidney Disease Therapeutics Company ProKidney to List on the Nasdaq
5:24pm
8-K
EX-10.11
u5cmqqrwknwd8c05 y0j
15 Jul 22
Revolutionary Chronic Kidney Disease Therapeutics Company ProKidney to List on the Nasdaq
5:24pm
DEFA14A
a06q bwcpfr650e
23 Jun 22
Additional proxy soliciting materials
4:31pm
DEFM14A
he0801k ci865k7nca
10 Jun 22
Proxy related to merger
4:54pm
DEFA14A
c1yuk2u8pt4
11 May 22
Additional proxy soliciting materials
4:55pm